MeSH tree: C20.683.780.650
March is Myeloma Awareness Month. Multiple myeloma is a blood cancer that most often occurs in people over age 45. It's the second-most common blood cancer and the most common blood cancer in Black people.
Mar 15, 2024
0
58
A new research paper titled "GZ17-6.02 interacts with proteasome inhibitors to kill multiple myeloma cells" has been published in Oncotarget.
Mar 6, 2024
0
24
Last year alone, David Mitchell paid $16,525 for 12 little bottles of Pomalyst, one of the pricey medications that treat his multiple myeloma, a blood cancer he was diagnosed with in 2010.
Feb 19, 2024
0
20
Immunotherapy is already improving treatment options for many cancer types, but research groups keep exploring ways to boost the body's immune response against the tumor.
Feb 14, 2024
0
56
Multiple myeloma remains challenging to treat. New therapeutic advances have improved outcomes, but selecting the right treatment for a patient can be complex because the disease can vary drastically from person to person. ...
Feb 9, 2024
0
54
A new research perspective titled "Preclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib in multiple myeloma" has been published in Oncotarget.
Feb 7, 2024
0
40
Cedars-Sinai Cancer investigators have discovered a protein expressed on multiple myeloma cancer cells that drives disease growth and development. The new study found that blocking part of the protein's unique signaling pathway ...
Feb 7, 2024
0
336
The U.S. Food and Drug Administration has told drugmakers to add a boxed warning to a type of cancer treatment called CAR-T therapy, saying the treatment itself may sometimes cause a secondary cancer.
Jan 24, 2024
0
33
The Dana Farber Cancer Institute in Boston will retract six studies and correct 31 more as part of an ongoing investigation into claims of data manipulation.
Jan 23, 2024
1
50
A new research perspective titled "Bone marrow adipocytes provide early sign for progression from mgus to multiple myeloma" has been published in Oncotarget.
Jan 22, 2024
0
36
